Palivizumab profilaksa RSV infekcije

Almira Ćosi?ki?, Jasminka Ibrahimovi?, Amela ?ikari?


Introduction: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children.

Material and methods: Observational study, in Tuzla Canton, Bosnia and Herzegovina (B&H), reports of infants at high risk for RSV who received at least 1 dose of palivizumab during the 2008-2016 RSV seasons.

Results: Across 8 RSV seasons, from 2008/9 to 2016/17, 267 infants were enrolled (0.66% of livebirths population). Of all infants,147 (55.0%) were enrolled for prematurity only, 7 (2.6%) for bronchopulmonary dysplasia/ chronic lung disease (BPD/CLD), 115 (43.0% ) for congenital heart disease (CHD), and 5 (1.8%) for other reasons; 129 (46.3%) infants in total were born before 33 weeks. Average gestational age of preterm infants enrolled for prematurity only was 30.1±1.2 weeks; for preterm infants with BPD/CLD it was 30±1.3weeks. Overall average of palivizumab injections was 3.9±1.1. Hospitalization rate related to severe lower respiratory infections (LRI) during the period of protection by palivizumab was 3.3%. Respiratory infections which deserved medical attention were observed in 6.3% infants included in palivizumab prophylaxis.

Conclusion: RSV prophylaxis in Tuzla Canton is provided systematically and successfully, following the national guidance established in 2009. with low hospitalization rate for severe LRI in prophylaxed infants..


Palivizumab, RSV prophylaxis, preterm infants, BPD/CLD, CHD.

DOI: 10.5457/ams.v47iSup 1.413